| Liquid biopsies come of age: towards implementation of circulating tumour DNA JCM Wan, C Massie, J Garcia-Corbacho, F Mouliere, JD Brenton, ... Nature Reviews Cancer 17 (4), 223-238, 2017 | 2306 | 2017 |
| Enhanced detection of circulating tumor DNA by fragment size analysis F Mouliere, D Chandrananda, AM Piskorz, EK Moore, J Morris, ... Science translational medicine 10 (466), eaat4921, 2018 | 872 | 2018 |
| The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial SK Sandhu, WR Schelman, G Wilding, V Moreno, RD Baird, S Miranda, ... The lancet oncology 14 (9), 882-892, 2013 | 626 | 2013 |
| First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors TA Yap, LI Yan, A Patnaik, I Fearen, D Olmos, K Papadopoulos, RD Baird, ... Journal of clinical oncology 29 (35), 4688-4695, 2011 | 623 | 2011 |
| A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds A Bruna, OM Rueda, W Greenwood, AS Batra, M Callari, RN Batra, ... Cell 167 (1), 260-274. e22, 2016 | 461 | 2016 |
| First-in-human phase I study of pictilisib (GDC-0941), a potent pan–class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors D Sarker, JE Ang, R Baird, R Kristeleit, K Shah, V Moreno, PA Clarke, ... Clinical cancer research 21 (1), 77-86, 2015 | 331 | 2015 |
| Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial P Schmid, J Abraham, S Chan, D Wheatley, AM Brunt, G Nemsadze, ... Journal of Clinical Oncology 38 (5), 423-433, 2020 | 328 | 2020 |
| Clinical development of new drug–radiotherapy combinations RA Sharma, R Plummer, JK Stock, TA Greenhalgh, O Ataman, S Kelly, ... Nature reviews Clinical oncology 13 (10), 627-642, 2016 | 296 | 2016 |
| PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot, RH Jones, H Eng, ... Molecular cancer 22 (1), 138, 2023 | 272 | 2023 |
| Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial NC Turner, B Kingston, LS Kilburn, S Kernaghan, AM Wardley, ... The Lancet Oncology 21 (10), 1296-1308, 2020 | 259 | 2020 |
| Drug resistance reversal—are we getting closer? RD Baird, SB Kaye European Journal of Cancer 39 (17), 2450-2461, 2003 | 190 | 2003 |
| Imaging breast cancer using hyperpolarized carbon-13 MRI FA Gallagher, R Woitek, MA McLean, AB Gill, R Manzano Garcia, ... Proceedings of the National Academy of Sciences 117 (4), 2092-2098, 2020 | 185 | 2020 |
| Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK AW Tolcher, K Khan, M Ong, U Banerji, V Papadimitrakopoulou, ... Clinical Cancer Research 21 (4), 739-748, 2015 | 143 | 2015 |
| A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with … B Venugopal, R Baird, RS Kristeleit, R Plummer, R Cowan, A Stewart, ... Clinical Cancer Research 19 (15), 4262-4272, 2013 | 132 | 2013 |
| Weekly paclitaxel in the treatment of recurrent ovarian cancer RD Baird, DSP Tan, SB Kaye Nature reviews Clinical oncology 7 (10), 575-582, 2010 | 126 | 2010 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 112 | 2019 |
| A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer EP Hamilton, MR Patel, AC Armstrong, RD Baird, K Jhaveri, M Hoch, ... Clinical Cancer Research 24 (15), 3510-3518, 2018 | 100 | 2018 |
| Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers TA Yap, L Yan, A Patnaik, N Tunariu, A Biondo, I Fearen, ... Clinical cancer research 20 (22), 5672-5685, 2014 | 83 | 2014 |
| Genetic heterogeneity in breast cancer: the road to personalized medicine? RD Baird, C Caldas BMC medicine 11, 1-5, 2013 | 82 | 2013 |
| AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled … P Schmid, J Abraham, S Chan, D Wheatley, M Brunt, G Nemsadze, ... J Clin Oncol 36 (15_suppl), 1007, 2018 | 79 | 2018 |
Johann de BonoInstitute of Cancer ResearchVerified email at icr.ac.uk
